Jay D. Kranzler, M.D., Ph.D. Chief Executive Officer and Chairman of the Board

Previously, Dr. Kranzler served as President, Chief Executive Officer and a Director of Cytel Corporation where he diversified Cytel's assets, raised $73 million through public offerings and acquired two technology companies, Glycogen and Receptor Laboratories, to augment the company's technology base. Under his leadership, Cytel secured five strategic alliances with major pharmaceutical companies - Upjohn, Sandoz, Sumitomo, Takara and Schwartz Pharma - which raised more than $150 million in research and development funding and equity investments. Dr. Kranzler founded Sequel Therapeutics in 1992 and served as President, Chief Executive Officer and Chairman of the Board for this joint venture with The Scripps Research Institute, which is now wholly owned by Cytel. He also co-founded Glytec Corporation in 1989 and served as President, Chief Executive Officer and Director until its acquisition by Cytel in 1990.

From 1985 to January 1989, Dr. Kranzler was a management consultant with the international consulting firm McKinsey & Company, where he worked with many of the world's leading pharmaceutical and technology companies conducting technology assessments, optimizing operating performance, evaluating research and development opportunities and structuring mergers and acquisitions.

At Yale University, Dr. Kranzler earned his M.D. with a concentration in Psychiatry and earned his Ph.D. in Pharmacology for his thesis work on biochemical gender differences in the brain. He graduated summa cum laude from Yeshiva University, where he was a Belkin Scholar. Dr. Kranzler is currently a lecturer at The Rady School of Business of the University of California San Diego, where he serves as Executive in Residence.

Sabrina Martucci Johnson Executive Vice President, Chief Operating Officer and Chief Financial Officer

Sabrina Martucci Johnson was appointed Chief Operating Officer in January 2008 and previously served as our Chief Business Officer. Ms. Johnson has served as our Chief Financial Officer since April 2002. Ms. Johnson joined the Company in August of 1998 and held various positions from 1998 through 2002, including Vice President Marketing. Ms. Johnson previously held marketing and sales positions with Advanced Tissue Sciences and Clonetics. Ms. Johnson has an MIM from the American Graduate School of International Management (Thunderbird) and a MSc. in Biochemical Engineering from the University of London, and a BSc. in Biomedical Engineering from Tulane University. Ms. Johnson began her career in the biotechnology industry as a research scientist with Baxter Healthcare, Hyland Division. Ms. Johnson currently serves on the audit committee of Project Concern International and on the Board of Advisors of the Tulane School of Science and Engineering and UCSD Libraries.

R. Michael Gendreau, M.D., Ph.D. Vice President Clinical Development, Chief Medical Officer

Dr. Gendreau is the longest serving member of the Cypress management team, having joined the company in 1994. He has 20+ years of experience in the development, clinical evaluation and commercialization of drug, biologic, medical device, and diagnostic products. Dr. Gendreau led the team that designed and managed Cypress' successful clinical programs resulting in FDA approval of the Company’s current flagship product, Savella (milnacipran HCI), for the management of fibromyalgia, as well as the Company’s former rheumatoid arthritis treatment, the Prosorba column. From 1991 to 1994, he served in various senior management roles in research, clinical development and regulatory affairs for Microprobe, Inc. of Seattle, WA, a biotechnology company developing oligonucleotide technology for diagnostic and therapeutic applications. From 1988 to 1991, Dr. Gendreau served as Vice President of research and development for Source Scientific Systems, a developer and manufacturer of OEM medical devices. From 1981 to 1988, Dr. Gendreau served as manager of worldwide Health Care Technology for the Battelle Memorial Institute of Columbus, OH. At Battelle, he served as a medical technology consultant, managed scientific and clinical development programs globally, supervised reimbursement and policy analysis, and developed diagnostic products. He also concurrently while at Battelle spent five years as Principal Investigator of the National Center for Biomedical Spectroscopy, an NIH funded center of excellence based on findings from Dr. Gendreau's doctoral research at Ohio State. Dr. Gendreau received his B.S. degree in Chemistry from Ohio University, and his M.D./Ph.D. degree in medicine and pharmacology from the Ohio State University, where he graduated summa cum laude.

Srinivas G. Rao, M.D., Ph.D. Chief Scientific Officer

Dr. Rao joined Cypress in August 2000 and has worked in a variety of areas, including scientific assessment of potential in-licensing compounds, business development, preclinical study design, design and execution of Cypress’ genomics program, and the development and maintenance of Cypress’ intellectual property portfolio. His current responsibilities also include heading Cypress’ commercial laboratory. Prior to Cypress, Dr. Rao worked as a free-lance medical electronics consultant while completing his combined M.D. and Ph.D. program at Yale Medical School. His Ph.D. research focused upon central nervous system neuropharmacology and took place in the laboratory of Dr. Patricia Goldman-Rakic, a world-renowned expert in working memory and pre-frontal function. Upon completion of his M.D. degree, Dr. Rao completed an internship in Internal Medicine at Yale-New Haven Hospital. Dr. Rao holds both an M.S. and B.S. from Yale University in Electrical Engineering.